, 166:121

Update on the Genus Trichosporon

  • Thomas C. Chagas-Neto
  • Guilherme M. Chaves
  • Arnaldo L. Colombo


Trichosporon spp. are widely distributed in nature and can occasionally belong to the human microbiota. For many years, the unique species of the genus, Trichosporon beigelli, was only known as an environmental and saprophytic fungus occasionally found as the etiological agent of white piedra. However, case reports of invasive trichosporonosis have been frequently published and the genus is currently considered the second most common agent of yeasts disseminated infections. Based on molecular analysis, the taxon T. beigelli was replaced by several species and the taxonomy of the genus was progressively modified. Despite the reported increase of Trichosporon infections refractory to conventional antifungal drugs, there are only a few studies investigating in vitro susceptibility of Trichosporon spp. to new compounds. Difficulties on different species identification as well as the lack of standardized sensitivity tests in vitro, contribute to the limited information available on epidemiology, diagnosis and therapeutics of trichosporonosis.


Emergent pathogen  Yeast identification Epidemiology Trichosporon Antifungal drugs 


  1. 1.
    Walsh TJ. Role of surveillance cultures in prevention and treatment of fungal infections. NCI Monogr. 1990;9:43–5.Google Scholar
  2. 2.
    Walsh TJ, Lee JW, Melcher GP, Navarro E, Bacher J, Callender D, et al. Experimental Trichosporon infection in persistently granulocytopenic rabbits: implications for pathogenesis, diagnosis, and treatment of an emerging opportunistic mycosis. J Infect Dis. 1992;166(1):121–33.PubMedGoogle Scholar
  3. 3.
    Lussier N, Laverdiere M, Delorme J, Weiss K, Dandavino R. Trichosporon beigelii funguria in renal transplant recipients. Clin Infect Dis. 2000;31(5):1299–301. doi:10.1086/317463.PubMedCrossRefGoogle Scholar
  4. 4.
    Walsh TJ, Groll A, Hiemenz J, Fleming R, Roilides E, Anaissie E. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect. 2004;10(Suppl 1):48–66. doi:10.1111/j.1470-9465.2004.00839.x.PubMedCrossRefGoogle Scholar
  5. 5.
    De Hoogs GS, Guarro J, Gene J, Figueras MJ. Atlas of clinical fungi. 2th ed. Rio de Janeiro: Guanabara; 2000.Google Scholar
  6. 6.
    Arce M, Arenas R. Infecções dermatológicas por Trichosporon beigelli: estudo retrospectivo de 12 casos em pacientes imunocompetentes. An Bras Dermatol. 1998;73:13–5.Google Scholar
  7. 7.
    Anaissie EJ, Bodey GP, Rinaldi MG. Emerging fungal pathogens. Eur J Clin Microbiol Infect Dis. 1989;8(4):323–30. doi:10.1007/BF01963467.PubMedCrossRefGoogle Scholar
  8. 8.
    Hoy J, Hsu KC, Rolston K, Hopfer RL, Luna M, Bodey GP. Trichosporon beigelii infection: a review. Rev Infect Dis. 1986;8(6):959–67.PubMedGoogle Scholar
  9. 9.
    Walsh TJ, Newman KR, Moody M, Wharton RC, Wade JC. Trichosporonosis in patients with neoplastic disease. Medicine. 1986;65(4):268–79. doi:10.1097/00005792-198607000-00005.PubMedCrossRefGoogle Scholar
  10. 10.
    Walsh TJ. Trichosporonosis. Infect Dis Clin North Am. 1989;3(1):43–52.PubMedGoogle Scholar
  11. 11.
    Herbrecht R, Waller J, Dufour P, Koenig H, Lioure B, Marcellin L, et al. Rare opportunistic fungal diseases in patients with organ or bone marrow transplantation. Agressologie: revue internationale de physio-biologie et de pharmacologie appliquees aux effets de l’agression. 1992;33(Spec No 2):77–80.Google Scholar
  12. 12.
    Gueho E, de Hoog GS, Smith MT. Neotypification of the genus Trichosporon. Antonie Van Leeuwenhoek. 1992;61(4):285–8. doi:10.1007/BF00713937.PubMedCrossRefGoogle Scholar
  13. 13.
    Gueho E, Smith MT, de Hoog GS, Billon-Grand G, Christen R, Batenburg-van der Vegte WH. Contributions to a revision of the genus Trichosporon. Antonie Van Leeuwenhoek. 1992;61(4):289–316. doi:10.1007/BF00713938.PubMedCrossRefGoogle Scholar
  14. 14.
    Behrend G. Ueber Trichomycosis nodosa (Juhel-Rénoy): Piedra (Osorio). Klin Wschr. 1890;27:464–7.Google Scholar
  15. 15.
    Sugita T, Nishikawa A, Shinoda T. Reclassification of Trichosporon cutaneum by DNA relatedness by using the spectrophotometric method and chemiluminometric method. J Gen Appl Microbiol. 1994;40:397–408. doi:10.2323/jgam.40.397.CrossRefGoogle Scholar
  16. 16.
    Sugita T, Nishikawa A, Shinoda T, Kume H. Taxonomic position of deep-seated, mucosa-associated, and superficial isolates of Trichosporon cutaneum from trichosporonosis patients. J Clin Microbiol. 1995;33(5):1368–70.PubMedGoogle Scholar
  17. 17.
    Gueho E, Improvisi L, de Hoog GS, Dupont B. Trichosporon on humans: a practical account. Mycoses. 1994;37(1–2):3–10.PubMedGoogle Scholar
  18. 18.
    Sugita T, Nakajima M, Ikeda R, Matsushima T, Shinoda T. Sequence analysis of the ribosomal DNA intergenic spacer 1 regions of Trichosporon species. J Clin Microbiol. 2002;40(5):1826–30. doi:10.1128/JCM.40.5.1826-1830.2002.PubMedCrossRefGoogle Scholar
  19. 19.
    Middelhoven WJ, Scorzetti G, Fell JW. Systematics of the anamorphic basidiomycetous yeast genus Trichosporon Behrend with the description of five novel species: Trichosporon vadense, T. smithiae, T. dehoogii, T. scarabaeorum and T. gamsii. Int J Syst Evol Microbiol 2004. 54(Pt 3):975–86. doi:10.1099/ijs.0.02859-0
  20. 20.
    Sugita T, Ikeda R, Nishikawa A. Analysis of Trichosporon isolates obtained from the houses of patients with summer-type hypersensitivity pneumonitis. J Clin Microbiol. 2004;42(12):5467–1. doi:10.1128/JCM.42.12.5467-5471.2004.PubMedCrossRefGoogle Scholar
  21. 21.
    Molnar O, Schatzmayr G, Fuchs E, Prillinger H. Trichosporon mycotoxinivorans sp. nov., a new yeast species useful in biological detoxification of various mycotoxins. Syst Appl Microbiol. 2004; 27(6):661–71. doi:10.1078/0723202042369947.
  22. 22.
    Fuentefria AM, Suh SO, Landell MF, Faganello J, Schrank A, Vainstein MH, et al. Trichosporon insectorum sp. nov., a new anamorphic basidiomycetous killer yeast. Mycol Res. 2008;112(Pt 1):93–9. doi:10.1016/j.mycres.2007.05.001.PubMedCrossRefGoogle Scholar
  23. 23.
    Fell JW, Scorzetti G. Reassignment of the basidiomycetous yeasts Trichosporon pullulans to Guehomyces pullulans gen nov. comb. nov., and Hyalodendron lignicola to Trichosporon lignicola comb. nov. Int J Syst Evol Microbiol. 2004;54(3):995–8. doi:10.1099/ijs.0.03017-0.PubMedCrossRefGoogle Scholar
  24. 24.
    Groll AH, Walsh TJ. Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect. 2001;7(Suppl 2):8–24. doi:10.1111/j.1469-0691.2001.tb00005.x.PubMedCrossRefGoogle Scholar
  25. 25.
    Kataoka-Nishimura S, Akiyama H, Saku K, Kashiwa M, Mori S, Tanikawa S, et al. Invasive infection due to Trichosporon cutaneum in patients with hematologic malignancies. Cancer 1998; 82(3):484–7. doi:10.1002/(SICI)1097-0142(19980201)82:3≤484::AID-CNCR9≥3.0.CO;2-P.Google Scholar
  26. 26.
    Archer-Dubon C, Orozco-Topete R, Leyva-Santiago J, Arenas R, Carbajosa J, Ysunza A. Superficial mycotic infections of the foot in a native pediatric population: a pathogenic role for Trichosporon cutaneum? Pediatr Dermatol. 2003;20(4):299–302. doi:10.1046/j.1525-1470.2003.20403.x.PubMedCrossRefGoogle Scholar
  27. 27.
    Krcmery V Jr, Mateicka F, Kunova A, Spanik S, Gyarfas J, Sycova Z, et al. Hematogenous trichosporonosis in cancer patients: report of 12 cases including 5 during prophylaxis with itraconazol. Support Care Cancer. 1999;7(1):39–43. doi:10.1007/s005200050221.PubMedCrossRefGoogle Scholar
  28. 28.
    Padhye AA, Verghese S, Ravichandran P, Balamurugan G, Hall L, Padmaja P, et al. Trichosporon loubieri infection in a patient with adult polycystic kidney disease. J Clin Microbiol. 2003;41(1):479–82. doi:10.1128/JCM.41.1.479-482.2003.PubMedCrossRefGoogle Scholar
  29. 29.
    Mendez-Tovar LJ, Anides-Fonseca A, Vazquez-Hernandez A, Galindo-Gonzalez M, Diaz-Madrid M, Berdon-Castro A, et al. Micosis among five highly underprivileged Mexican communities. Gac Med Mex. 2006;142(5):381–6.PubMedGoogle Scholar
  30. 30.
    Ruiz-Esmenjaud J, Arenas R, Rodriguez-Alvarez M, Monroy E, Felipe Fernandez R. Tinea pedis and Onychomycosis in Children of the Mazahua Indian Community in Mexico. Gac Med Mex. 2003;139(3):215–20.PubMedGoogle Scholar
  31. 31.
    Pontes ZB, Ramos AL, Lima Ede O, Guerra Mde F, Oliveira NM, Santos JP. Clinical and mycological study of scalp white piedra in the State of Paraiba, Brazil. Mem Inst Oswaldo Cruz. 2002;97(5):747–50. doi:10.1590/S0074-02762002000500028.PubMedCrossRefGoogle Scholar
  32. 32.
    Nishiura Y, Nakagawa-Yoshida K, Suga M, Shinoda T, Gueho E, Ando M. Assignment and serotyping of Trichosporon species: the causative agents of summer-type hypersensitivity pneumonitis. J Med Vet Mycol. 1997;35(1):45–52. doi:10.1080/02681219780000861.PubMedCrossRefGoogle Scholar
  33. 33.
    Therizol-Ferly M, Kombila M, Gomez de Diaz M, Douchet C, Salaun Y, Barrabes A, et al. White piedra and Trichosporon species in equatorial Africa. II. Clinical and mycological associations: an analysis of 449 superficial inguinal specimens. Mycoses. 1994;37(7–8):255–60.PubMedGoogle Scholar
  34. 34.
    Yoo CG, Kim YW, Han SK, Nakagawa K, Suga M, Nishiura Y, et al. Summer-type hypersensitivity pneumonitis outside Japan: a case report and the state of the art. Respirology (Carlton, Vic.) 1997;2(1):75–7.CrossRefGoogle Scholar
  35. 35.
    Kaltreider HB. Hypersensitivity pneumonitis. West J Med. 1993;159(5):570–8.PubMedGoogle Scholar
  36. 36.
    Mizobe T, Ando M, Yamasaki H, Onoue K, Misaki A. Purification and characterization of the serotype-specific polysaccharide antigen of Trichosporon cutaneum serotype II: a disease-related antigen of Japanese summer-type hypersensitivity pneumonitis. Clin Exp Allergy. 1995;25(3):265–72. doi:10.1111/j.1365-2222.1995.tb01039.x.PubMedCrossRefGoogle Scholar
  37. 37.
    Fleming RV, Walsh TJ, Anaissie EJ. Emerging and less common fungal pathogens. Infect Dis Clin North Am. 2002;16(4):915–33, vi–vii. doi:10.1016/S0891-5520(02)00041-7
  38. 38.
    Colombo AL, Melo AS, Crespo Rosas RF, Salomao R, Briones M, Hollis RJ, et al. Outbreak of Candida rugosa candidemia: an emerging pathogen that may be refractory to amphotericin B therapy. Diagn Microbiol Infect Dis. 2003;46(4):253–7. doi:10.1016/S0732-8893(03)00079-8.PubMedCrossRefGoogle Scholar
  39. 39.
    da Matta VL, de Souza Carvalho Melhem M, Colombo AL, Moretti ML, Rodero L, Duboc de Almeida GM, et al. Antifungal drug susceptibility profile of Pichia anomala isolates from patients presenting with nosocomial fungemia. Antimicrob Agents Chemother. 2007;51(4):1573–6. doi:10.1128/AAC.01038-06.PubMedCrossRefGoogle Scholar
  40. 40.
    Pasqualotto AC, Sukiennik TC, Severo LC, de Amorim CS, Colombo AL. An outbreak of Pichia anomala fungemia in a Brazilian pediatric intensive care unit. Infect Control Hosp Epidemiol. 2005;26(6):553–8. doi:10.1086/502583.PubMedCrossRefGoogle Scholar
  41. 41.
    Tuon FF, de Almeida GM, Costa SF. Central venous catheter-associated fungemia due to Rhodotorula spp.—a systematic review. Med Mycol. 2007;45(5):441–7. doi:10.1080/13693780701381289.PubMedCrossRefGoogle Scholar
  42. 42.
    Manzella JP, Berman IJ, Kukrika MD. Trichosporon beigelii fungemia and cutaneous dissemination. Arch Dermatol. 1982;118(5):343–5. doi:10.1001/archderm.118.5.343.PubMedCrossRefGoogle Scholar
  43. 43.
    Reinhart HH, Urbanski DM, Harrington SD, Sobel JD. Prosthetic valve endocarditis caused by Trichosporon beigelii. Am J Med. 1988;84(2):355–8. doi:10.1016/0002-9343(88)90440-8.PubMedCrossRefGoogle Scholar
  44. 44.
    Lopes JO, Alves SH, Klock C, Oliveira LT, Dal Forno NR. Trichosporon inkin peritonitis during continuous ambulatory peritoneal dialysis with bibliography review. Mycopathologia. 1997;139(1):15–8. doi:10.1023/A:1006870017725.PubMedCrossRefGoogle Scholar
  45. 45.
    Moretti-Branchini ML, Fukushima K, Schreiber AZ, Nishimura K, Papaiordanou PM, Trabasso P, et al. Trichosporon species infection in bone marrow transplanted patients. Diagn Microbiol Infect Dis. 2001;39(3):161–4. doi:10.1016/S0732-8893(01)00215-2.PubMedCrossRefGoogle Scholar
  46. 46.
    Meyer MH, Letscher-Bru V, Waller J, Lutz P, Marcellin L, Herbrecht R. Chronic disseminated Trichosporon asahii infection in a leukemic child. Clin Infect Dis. 2002;35(2):e22–5. doi:10.1086/340983.PubMedCrossRefGoogle Scholar
  47. 47.
    Abdala E, Lopes RI, Chaves CN, Heins-Vaccari EM, Shikanai-Yasuda MA. Trichosporon asahii fatal infection in a non-neutropenic patient after orthotopic liver transplantation. Transpl Infect Dis. 2005;7(3–4):162–5. doi:10.1111/j.1399-3062.2005.00104.x.PubMedCrossRefGoogle Scholar
  48. 48.
    Girmenia C, Pagano L, Martino B, D’Antonio D, Fanci R, Specchia G, et al. Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature. J Clin Microbiol. 2005;43(4):1818–28. doi:10.1128/JCM.43.4.1818-1828.2005.PubMedCrossRefGoogle Scholar
  49. 49.
    Herbrecht R, Liu KL, Koenig H, Waller J, Dufour P, Marcellin L, et al. [Trichosporon capitatum septicemia. Apropos of 5 cases]. Agressologie: revue internationale de physio-biologie et de pharmacologie appliquees aux effets de l’agression. 1992;33(Spec No 2):96–8.Google Scholar
  50. 50.
    Rastogi VL, Nirwan PS. Invasive trichosporonosis due to Trichosporon asahii in a non-immunocompromised host: a rare case report. Indian J Med Microbiol. 2007;25(1):59–61.PubMedGoogle Scholar
  51. 51.
    Rodriguez-Tudela JL, Diaz-Guerra TM, Mellado E, Cano V, Tapia C, Perkins A, et al. Susceptibility patterns and molecular identification of Trichosporon species. Antimicrob Agents Chemother. 2005;49(10):4026–34. doi:10.1128/AAC.49.10.4026-4034.2005.PubMedCrossRefGoogle Scholar
  52. 52.
    Ciardo DE, Schar G, Bottger EC, Altwegg M, Bosshard PP. Internal transcribed spacer sequencing versus biochemical profiling for identification of medically important yeasts. J Clin Microbiol. 2006;44(1):77–84. doi:10.1128/JCM.44.1.77-84.2006.PubMedCrossRefGoogle Scholar
  53. 53.
    Sugita T, Nishikawa A, Shinoda T. Rapid detection of species of the opportunistic yeast Trichosporon by PCR. J Clin Microbiol. 1998;36(5):1458–60.PubMedGoogle Scholar
  54. 54.
    Pincus DH, Orenga S, Chatellier S. Yeast identification—past, present, and future methods. Med Mycol. 2007;45(2):97–121. doi:10.1080/13693780601059936.PubMedCrossRefGoogle Scholar
  55. 55.
    Arikan S, Hascelik G. Comparison of NCCLS microdilution method and Etest in antifungal susceptibility testing of clinical Trichosporon asahii isolates. Diagn Microbiol Infect Dis. 2002;43(2):107–11. doi:10.1016/S0732-8893(02)00376-0.PubMedCrossRefGoogle Scholar
  56. 56.
    Perparim K, Nagai H, Hashimoto A, Goto Y, Tashiro T, Nasu M. In vitro susceptibility of Trichosporon beigelii to antifungal agents. J Chemother (Florence, Italy). 1996;8(6):445–8.Google Scholar
  57. 57.
    Uzun O, Arikan S, Kocagoz S, Sancak B, Unal S. Susceptibility testing of voriconazole, fluconazole, itraconazole and amphotericin B against yeast isolates in a Turkish University Hospital and effect of time of reading. Diagn Microbiol Infect Dis. 2000;38(2):101–7. doi:10.1016/S0732-8893(00)00177-2.PubMedCrossRefGoogle Scholar
  58. 58.
    Pfaller MA, Bale M, Buschelman B, Lancaster M, Espinel-Ingroff A, Rex JH, et al. Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine. J Clin Microbiol. 1995;33(5):1104–7.PubMedGoogle Scholar
  59. 59.
    Sugita T, Makimura K, Nishikawa A, Uchida K, Yamaguchi H, Shinoda T. Partial sequences of large subunit ribosomal DNA of a new yeast species, Trichosporon domesticum and related species. Microbiol Immunol. 1997;41(7):571–3.PubMedGoogle Scholar
  60. 60.
    Sugita T, Nishikawa A, Ikeda R, Shinoda T. Identification of medically relevant Trichosporon species based on sequences of internal transcribed spacer regions and construction of a database for Trichosporon identification. J Clin Microbiol. 1999;37(6):1985–93.PubMedGoogle Scholar
  61. 61.
    Rodriguez-Tudela JL, Gomez-Lopez A, Alastruey-Izquierdo A, Mellado E, Bernal-Martinez L, Cuenca-Estrella M. Genotype distribution of clinical isolates of Trichosporon asahii based on sequencing of intergenic spacer 1. Diagn Microbiol Infect Dis. 2007;58(4):435–40. doi:10.1016/j.diagmicrobio.2007.03.001.PubMedCrossRefGoogle Scholar
  62. 62.
    Diaz MR, Fell JW. High-throughput detection of pathogenic yeasts of the genus trichosporon. J Clin Microbiol. 2004;42(8):3696–706. doi:10.1128/JCM.42.8.3696-3706.2004.PubMedCrossRefGoogle Scholar
  63. 63.
    EUCAST. Definitive Document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect. 2008;14(4):398–405. doi:10.1111/j.1469-0691.2007.01935.x.CrossRefGoogle Scholar
  64. 64.
    Chaturvedi V, Ramani R, Rex JH. Collaborative study of antibiotic medium 3 and flow cytometry for identification of amphotericin B-resistant Candida isolates. J Clin Microbiol. 2004;42(5):2252–4. doi:10.1128/JCM.42.5.2252-2254.2004.PubMedCrossRefGoogle Scholar
  65. 65.
    Hospenthal DR, Murray CK, Rinaldi MG. The role of antifungal susceptibility testing in the therapy of candidiasis. Diagn Microbiol Infect Dis. 2004;48(3):153–60. doi:10.1016/j.diagmicrobio.2003.10.003.PubMedCrossRefGoogle Scholar
  66. 66.
    Hata K, Kimura J, Miki H, Toyosawa T, Nakamura T, Katsu K. In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum. Antimicrob Agents Chemother. 1996;40(10):2237–42.PubMedGoogle Scholar
  67. 67.
    Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, Rex JH. In vitro antifungal susceptibilities of Trichosporon species. Antimicrob Agents Chemother. 2002;46(4):1144–6. doi:10.1128/AAC.46.4.1144-1146.2002.PubMedCrossRefGoogle Scholar
  68. 68.
    Anaissie E, Gokaslan A, Hachem R, Rubin R, Griffin G, Robinson R, et al. Azole therapy for trichosporonosis: clinical evaluation of eight patients, experimental therapy for murine infection, and review. Clin Infect Dis. 1992;15(5):781–7.PubMedGoogle Scholar
  69. 69.
    Tawara S, Ikeda F, Maki K, Morishita Y, Otomo K, Teratani N, et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother. 2000;44(1):57–62.PubMedGoogle Scholar
  70. 70.
    Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol. 2004;42(10):4419–31. doi:10.1128/JCM.42.10.4419-4431.2004.PubMedCrossRefGoogle Scholar
  71. 71.
    Walsh TJ, Melcher GP, Rinaldi MG, Lecciones J, McGough DA, Kelly P, et al. Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol. 1990;28(7):1616–22.PubMedGoogle Scholar
  72. 72.
    Anaissie EJ, Hachem R, Karyotakis NC, Gokaslan A, Dignani MC, Stephens LC, et al. Comparative efficacies of amphotericin B, triazoles, and combination of both as experimental therapy for murine trichosporonosis. Antimicrob Agents Chemother. 1994;38(11):2541–4.PubMedGoogle Scholar
  73. 73.
    Itoh T, Hosokawa H, Kohdera U, Toyazaki N, Asada Y. Disseminated infection with Trichosporon asahii. Mycoses. 1996;39(5–6):195–9.PubMedCrossRefGoogle Scholar
  74. 74.
    Kim JC, Kim YS, Park CS, Kang JM, Kim BN, Woo JH, et al. A case of disseminated Trichosporon beigelii infection in a patient with myelodysplastic syndrome after chemotherapy. J Korean Med Sci. 2001;16(4):505–8.PubMedGoogle Scholar
  75. 75.
    Karabay O, Madariaga MG, Kocoglu E, Ince N, Kandirali E. Trichosporon asahii fungemia in a patient with non-hematological malignancy. Jpn J Infect Dis. 2006;59(2):129–31.PubMedGoogle Scholar
  76. 76.
    Makimura K, Suzuki T, Tamura T, Ikedo M, Hanazawa R, Takahashi Y, et al. Comparative evaluation of standard dilution method and commercial kit for frozen plate antifungal susceptibility testing of yeasts using 200 clinical isolates. Microbiol Immunol. 2004;48(10):747–53.PubMedGoogle Scholar
  77. 77.
    Wolf DG, Falk R, Hacham M, Theelen B, Boekhout T, Scorzetti G, et al. Multidrug-resistant Trichosporon asahii infection of nongranulocytopenic patients in three intensive care units. J Clin Microbiol. 2001;39(12):4420–5. doi:10.1128/JCM.39.12.4420-4425.2001.PubMedCrossRefGoogle Scholar
  78. 78.
    Goodman D, Pamer E, Jakubowski A, Morris C, Sepkowitz K. Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate. Clin Infect Dis. 2002;35(3):E35–6. doi:10.1086/341305.PubMedCrossRefGoogle Scholar
  79. 79.
    Cornely OA, Schmitz K, Aisenbrey S. The first echinocandin: caspofungin. Mycoses. 2002;45(Suppl 3):56–60.PubMedGoogle Scholar
  80. 80.
    Espinel-Ingroff A. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743, 872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol. 1998;36(10):2950–6.PubMedGoogle Scholar
  81. 81.
    Bassetti M, Bisio F, Di Biagio A, Pierri I, Balocco M, Soro O, et al. Trichosporon asahii infection treated with caspofungin combined with liposomal amphotericin B. J Antimicrob Chemother. 2004;54(2):575–7. doi:10.1093/jac/dkh337.PubMedCrossRefGoogle Scholar
  82. 82.
    Asada N, Uryu H, Koseki M, Takeuchi M, Komatsu M, Matsue K. Successful treatment of breakthrough Trichosporon asahii fungemia with voriconazole in a patient with acute myeloid leukemia. Clin Infect Dis. 2006;43(4):e39–41. doi:10.1086/505970.PubMedCrossRefGoogle Scholar
  83. 83.
    Fournier S, Pavageau W, Feuillhade M, Deplus S, Zagdanski AM, Verola O, et al. Use of voriconazole to successfully treat disseminated Trichosporon asahii infection in a patient with acute myeloid leukaemia. Eur J Clin Microbiol Infect Dis. 2002;21(12):892–6.PubMedGoogle Scholar
  84. 84.
    Matsue K, Uryu H, Koseki M, Asada N, Takeuchi M. Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin. Clin Infect Dis. 2006;42(6):753–7. doi:10.1086/500323.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2008

Authors and Affiliations

  • Thomas C. Chagas-Neto
    • 1
  • Guilherme M. Chaves
    • 1
  • Arnaldo L. Colombo
    • 1
  1. 1.Division of Infectious DiseasesUniversidade Federal de São PauloSao PauloBrazil

Personalised recommendations